Dark

Check out our Level2View

CARA
Cara Therapeutics, Inc.
stock NASDAQ

Inactive

Apr 15, 2025

15.96USD-4.142%(-0.69)79,048

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-16.65)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

08:34AM EST Cara Therapeutics Announces Difelikefalin Injection Topline Results In Phase 3 Clinical Study In Japan Benzinga

08:00AM EST Cara Therapeutics Announces Difelikefalin GlobeNewswire Inc

Jan 3, 2022

04:35PM EST Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences, Sotera Health, Eagle Pharma Benzinga

04:12PM EST Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences Benzinga

04:03PM EST Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights Benzinga

04:01PM EST Cara Therapeutics to Present at the 40th Annual J.P. Morgan GlobeNewswire Inc

Dec 20, 2021

07:18AM EST Cara Therapeutics: CMS Grants TDAPA To KORSUVA Injection In Anti-pruritic Functional Category RTTNews

07:08AM EST Cara Therapeutics Announces The CMS Has Granted Transitional Drug Add-On Payment Adjustment To KORSUVA Injection Benzinga

07:00AM EST Cara Therapeutics Announces CMS Grants TDAPA to GlobeNewswire Inc

Nov 18, 2021

08:30AM EST Cara Therapeutics to Present at the Piper Sandler 33rd Annual GlobeNewswire Inc

Nov 9, 2021

11:06AM EST Cara Therapeutics Q3 EPS $(0.02) Beats $(0.40) Estimate, Sales $20.27M Beat $11.21M Estimate Benzinga

Nov 8, 2021

04:01PM EST KORSUVA (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administration (FDA) GlobeNewswire Inc

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 3, 2021

09:42AM EDT Cara Therapeutics Option Alert: Dec 17 $20 Calls at the Ask: 750 @ $1.0 vs 2509 OI; Earnings 11/16 After Close [est] Ref=$17.34 Benzinga

09:19AM EDT Cara Therapeutics Appoints Christopher Posner President And CEO Benzinga

08:00AM EDT Cara Therapeutics Announces CEO Transition GlobeNewswire Inc

Nov 1, 2021

04:15PM EDT Cara Therapeutics to Announce Third Quarter 2021 Financial Results GlobeNewswire Inc

Oct 7, 2021

05:10PM EDT Bullish Sentiment For Marijuana Stocks: Tilray, GrowGeneration & Canopy Growth Among Top Cannabis Movers For October 7, 2021 Benzinga

Oct 4, 2021

07:30AM EDT Cara Therapeutics Presents Results Of KARE Phase 2 Trial Of Oral KORSUVA At EADV Congress RTTNews

07:01AM EDT Cara Therapeutics Presents Late-Breaking Results Of KARE Phase 2 Trial Of Oral Difelikefalin In Atopic Dermatitis Patients With Moderate-to-Severe Pruritus At The 2021 European Academy Of Dermatology And Venereology Virtual Congress Benzinga

07:00AM EDT Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 GlobeNewswire Inc

Sep 29, 2021

07:14AM EDT Cara Therapeutics Announces Late-Breaking Presentation At 2021 European Academy Of Dermatology And Venereology (EADV) Virtual Congress Oct. 2 Benzinga

07:00AM EDT Cara Therapeutics Announces Late-Breaking Presentation at 2021 GlobeNewswire Inc

Sep 24, 2021

07:00AM EDT Cara Therapeutics to Present at the the 2021 Cantor Virtual Global GlobeNewswire Inc

Sep 22, 2021

10:18AM EDT Grove's Acquisitions Fueling Company's Growth Benzinga

Sep 2, 2021

10:15AM EDT Cara Therapeutics Sponsored Study Titled 'Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin' Posted To ClinicalTrials.gov; Shows Expanded Access Status Is Available Benzinga

Aug 24, 2021

10:58AM EDT Why Is Cara Therapeutics Stock Trading Higher Today? Benzinga

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

06:13AM EDT HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Raises Price Target to $35 Benzinga

05:57AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 5.45 A.M. EDT). RTTNews

01:16AM EDT The U.S. Food and Drug Administration has approved Korsuva or difelikefalin for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis, Vifor Pharma and Cara Therapeutics (CARA) said in a statement on Tuesday. RTTNews

01:04AM EDT Vifor Pharma, Cara Therapeutics: FDA Approves KORSUVA Injection For Moderate-to-severe Pruritus In Hemodialysis Patients RTTNews

01:00AM EDT Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA(tm) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients Business Wire

Aug 23, 2021

03:43PM EDT Cara Therapeutics And Vifor Pharma Announce FDA Approval Of KORSUVA For Treatment Of Moderate-To-Severe Pruritus In Hemodialysis Patients Benzinga

03:41PM EDT -- First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis -- Promotional launch of KORSUVA injection in the U.S. is expected in Q1 2022, with reimbursement in H1 2022 -- Company to host conference call today at 5.00 p.m. ET GlobeNewswire Inc

Aug 9, 2021

04:56PM EDT Cara Therapeutics: Q2 Earnings Insights Benzinga

04:09PM EDT Cara Therapeutics Q2 EPS $(0.61) Misses $(0.53) Estimate Benzinga

04:01PM EDT New Drug Application (NDA) Filing for KORSUVA Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 GlobeNewswire Inc

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

06:18AM EDT Cara Therapeutics Announces Agreement Defines Responsibilities With Respect To PPL's Manufacture, Supply Of Active Pharmaceutical Agreement Difelikefalin; Agreement Covers PPl's Manufacture, Supply Of Active Pharmaceutical Agreement Difelikefalin For Co's Korsuva I.V. Product Candidate Benzinga

06:18AM EDT Cara Therapeutics Announces Agreement Defines Responsibilities With Respect To PPL's Manufacture, Supply Of Active Pharmaceutical Agreement Difelikefalin; Agreement Covers PPl's Manufacture, Supply Of Active Pharmaceutical Agreement Difelikefalin For Co's Benzinga

06:07AM EDT Cara Therapeutics - On July 26, Entered Into API Commercial Supply Agreement With Polypeptide Laboratories S.A Benzinga

Aug 3, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021 Benzinga

05:10AM EDT JP Morgan Initiates Coverage On Cara Therapeutics with Neutral Rating, Announces Price Target of $16 Benzinga

Aug 2, 2021

06:10PM EDT Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates Benzinga

04:01PM EDT Cara Therapeutics to Announce Second Quarter 2021 Financial GlobeNewswire Inc

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 20, 2021

06:03PM EDT Bullish Sentiment Pumps Up Cannabis Stocks: Tilray, Sundial, Aurora & GrowGen Among Top Cannabis Movers For July 20, 2021 Benzinga

Jul 14, 2021

07:14AM EDT General Cannabis, MariMed & Urban-Gro Among Top Cannabis Stock Movers On July 13, 2021 Benzinga

Jun 22, 2021

10:18AM EDT Cara Therapeutics Insights: Return On Capital Employed Benzinga

Jun 15, 2021

03:34PM EDT Cara Therapeutics Granted U.S. Patent Titled 'Oral formulations of kappa opioid receptor agonists' Benzinga

Jun 11, 2021

07:35AM EDT SWK Holdings Reports Its Wholly-Owned Subsidiary, Enteris BioPharma, Received $10M Milestone Payment From Cara Therapeutics For Licese Deal On Peptelligence Oral Formulation Benzinga

07:30AM EDT SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone PR Newswire

Jun 3, 2021

11:15AM EDT Cara Therapeutics: Return On Capital Employed Insights Benzinga

May 25, 2021

07:00AM EDT Cara Therapeutics to Present at the Jefferies Healthcare Conference GlobeNewswire Inc

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 11, 2021

05:02PM EDT Cannabis Stock Gainers And Losers From May 11, 2021 Benzinga

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 10, 2021

04:49PM EDT Cara Therapeutics: Q1 Earnings Insights Benzinga

04:16PM EDT Cara Therapeutics Q1 EPS $(0.47) Beats $(0.59) Estimate, Sales $1.935M Miss $2.36M Estimate Benzinga

04:01PM EDT U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA Injection in CKD-aP GlobeNewswire Inc

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 3, 2021

04:01PM EDT Cara Therapeutics to Announce First Quarter 2021 Financial Results GlobeNewswire Inc

Apr 30, 2021

07:27PM EDT Cannabis Stock Gainers And Losers From April 30, 2021 Benzinga

Apr 29, 2021

02:30PM EDT Mid-Afternoon Market Update: Dow Gains 175 Points; JAKKS Pacific Shares Climb After Q1 Results Benzinga

12:47PM EDT Mid-Day Market Update: Nasdaq Turns Lower; Galera Therapeutics Shares Surge Benzinga

12:25PM EDT Needham Maintains Buy on Cara Therapeutics, Lowers Price Target to $26 Benzinga

10:28AM EDT Cara Therapeutics, Inc. (CARA) shares are sliding more than 42 percent on Thursday morning trade after the company said its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA failed to meet the primary endpoint of worst-itch NRS change baseline for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients. RTTNews

10:24AM EDT Mid-Morning Market Update: Markets Open Higher; McDonald's Profit Beats Estimates Benzinga

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

08:15AM EDT Cara Therapeutics' Stock Plummets As Korsuva Flunks In Mid-Stage Atopic Dermatitis Study Benzinga

07:31AM EDT Cara Therapeutics Announces Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus Did Not Meet Primary Endpoint Benzinga

07:00AM EDT Study did not meet Primary Endpoint of worst-itch NRS change from baseline at week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population GlobeNewswire Inc

Apr 23, 2021

07:26PM EDT Cannabis Stock Gainers And Losers From April 23, 2021 Benzinga

Apr 7, 2021

04:01PM EDT Cara Therapeutics to Present at the 20th Annual Needham Healthcare GlobeNewswire Inc

10:11AM EDT Cara Therapeutics Shares Down ~1% Ahead Of Co's Virtual R&D Event Beginning At 1 p.m. EDT Benzinga

07:58AM EDT The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award Benzinga

Apr 6, 2021

08:05AM EDT The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout Benzinga

Apr 5, 2021

06:56PM EDT Cara Therapeutics Set to Join S&P SmallCap 600 PR Newswire

05:18PM EDT S&P Dow Jones Indices Announces Cara Therapeutics To Replace MTS Systems In S&P SmallCap 600 Benzinga

Mar 31, 2021

07:00AM EDT Cara Therapeutics to Host Virtual Research and Development Event GlobeNewswire Inc

Mar 30, 2021

01:41AM EDT Cara Therapeutics Inc. (CARA) and Vifor Fresenius Medical Care Renal Pharma said that the European Medicines Agency or EMA accepted to review the Marketing Authorization Application or MAA for difelikefalin injection for the treatment of pruritus associated with chronic kidney disease in hemodialysis patients. RTTNews

01:05AM EDT VFMCRP And Cara Therapeutics: EMA Accepts To Review MAA For Difelikefalin Injection RTTNews

01:00AM EDT -- Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin -- If approved, difelikefalin injection will be the first therapy available in Europe for treatment of pruritus associated with chronic kidney disease in hemodialysis patients GlobeNewswire Inc

Mar 8, 2021

08:40AM EST Cara Therapeutics/Vifor Pharma's Korsuva US Application In Pruritus Accepted For Review Benzinga

01:04AM EST Vifor Pharma And Cara Therapeutics: FDA Accepted And Granted Priority Review For NDA For KORSUVA Solution RTTNews

01:00AM EST Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA(tm)* injection in hemodialysis patients with moderate-to-severe pruritus Business Wire

01:00AM EST -- FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021 -- If approved, KORSUVA injection would be first therapy for treatment of pruritus in hemodialysis patients GlobeNewswire Inc

Feb 25, 2021

04:05PM EST Cara Therapeutics Q4 EPS $1.59 May Not Compare To $0.36 Estimate, Sales $112.09M May Not Compare To $48.63M Estimate Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 24, 2021

10:13AM EST Preview: Cara Therapeutics's Earnings Benzinga

Feb 18, 2021

04:01PM EST Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 11, 2021

07:30AM EST Cara Announces Initiation Of Phase 2 Trial Of Oral KORSUVA RTTNews

07:05AM EST Cara Initiates Phase 2 Trial of Oral KORSUVA for the Treatment of Pruritus in Patients with Notalgia Paresthetica Benzinga

07:00AM EST Cara Initiates Phase 2 Trial of Oral KORSUVA for GlobeNewswire Inc

Jan 6, 2021

07:00AM EST Cara Therapeutics to Present at the 39th Annual J.P. Morgan GlobeNewswire Inc

Dec 28, 2020

07:02AM EST Cara Therapeutics Submits a New Drug Application to the FDA for KORSUVA in Hemodialysis Patients with Moderate-to-Severe Pruritus Benzinga

07:00AM EST -- First NDA submission for Companys lead program, KORSUVA Injection -- NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection GlobeNewswire Inc

Dec 26, 2020

09:16AM EST The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks Benzinga

Dec 24, 2020

07:48AM EST SWK Holdings Corp. (SWKH), a specialty finance company focused on life sciences, said Thursday that its wholly-owned subsidiary, Enteris BioPharma, received a second milestone payment of $2.5 million from Cara Therapeutics (CARA). RTTNews

07:32AM EST SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment Of $2.5 Mln From Cara Therapeutics RTTNews

07:30AM EST SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment PR Newswire

Dec 22, 2020

04:44PM EST Cannabis Stock Gainers And Losers From December 22, 2020 Benzinga

04:05PM EST CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors GlobeNewswire Inc

Dec 2, 2020

07:15AM EST Cara Therapeutics Completes Full Enrollment In KARE Phase 2 Trial Of Oral KORSUVA In Atopic Dermatitis Patients With Moderate-To-Severe Pruritus Benzinga

07:00AM EST Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial GlobeNewswire Inc

Nov 11, 2020

07:00AM EST Cara Therapeutics to Present at Multiple Upcoming Investor Conferences GlobeNewswire Inc

Nov 9, 2020

04:52PM EST Cara Therapeutics: Q3 Earnings Insights Benzinga

04:03PM EST Cara Therapeutics Q3 EPS $(0.35) Beats $(0.60) Estimate, Sales $9.27M Beat $4.77M Estimate Benzinga

04:01PM EST Cara Therapeutics Reports Third Quarter 2020 Financial Results GlobeNewswire Inc

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 4, 2020

05:33PM EST Cannabis Stock Gainers And Losers From November 4, 2020 Benzinga

Nov 2, 2020

04:01PM EST Cara Therapeutics to Announce Third Quarter 2020 Financial Results GlobeNewswire Inc

Oct 27, 2020

04:25PM EDT SWK Holdings Subsidiary Enteris BioPharma Announces It Received A Milestone Paumeny Of $2.5M From Cara Therapeutics Benzinga

04:06PM EDT SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from PR Newswire

Oct 21, 2020

04:02PM EDT Cara Therapeutics Announces Presentation Of Results From Global KALM-2 Pivotal Phase 3 Trial Of KORSUVA Injection In Hemodialysis Patients With Pruritus At American Society Of Nephrology Kidney Week 2020 Benzinga

04:01PM EDT - Results from global KALM-2 pivotal Phase 3 trial of KORSUVA Injection in hemodialysis patients with pruritus to be presented GlobeNewswire Inc

Oct 20, 2020

03:30PM EDT Why Cara Therapeutics Stock Is Trading Higher Today Benzinga

10:27AM EDT Shares of Cara Therapeutics, Inc. (CARA) are climbing more than 3% Tuesday morning on signing license agreement with Vifor Pharma to commercialize IV Korsuva, Cara's late-stage drug in chronic kidney disease-associated pruritus(CKD-aP). RTTNews

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

05:51AM EDT Vifor Pharma and Cara Therapeutics Signed US License Agreement for IV Korsuva to Treat Dialysis Patients with Pruritus; Cara to Receive Upfront Payment of $100M in Cash and an Equity Investment of $50M Benzinga

01:00AM EDT Vifor Pharma and Cara Therapeutics sign US license agreement for GlobeNewswire Inc

Oct 15, 2020

08:14AM EDT Titan Pharmaceuticals Provides Strategic & Corporate Update Benzinga

Oct 1, 2020

07:06AM EDT Cara Therapeutics Announces The Appointment Of Thomas Reilly As CFO Benzinga

07:00AM EDT Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer GlobeNewswire Inc

Aug 10, 2020

04:31PM EDT Cara Therapeutics Q2 EPS $(0.54) Beats $(0.67) Estimate, Sales $5.63M Beat $5.06M Estimate Benzinga

04:01PM EDT Cara Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 3, 2020

04:01PM EDT Cara Therapeutics to Announce Second Quarter 2020 Financial GlobeNewswire Inc

Share